Charles River Laboratories has acquired Blue Stream Laboratories, an analytical CRO that helps develop complex biologics and biosimilars. Blue Stream is specifically known for its expertise in structural and functional protein characterization and the development and validation of assays for Current Good Manufacturing Practice (cGMP) lot release and stability programs.
According to James C. Foster, chairman, president, and CEO, “Our continued investment in expanding our biologics portfolio, through the development of new assays and capabilities, has enabled us to provide a broader testing solution for our clients. This investment is particularly important now, when the number of biologic and biosimilar drugs in development is increasing. The acquisition of Blue Stream will meaningfully enhance the ability of our Biologic Testing Solutions business to compete effectively in this high-growth market segment.”
In January, Charles River acquired WIL Research for about $585 million. The deal was said to enhance Charles River’s global footprint, scientific capabilities, and access to growing markets.
In addition, late last year, Charles River acquired the German CRO Oncotest, which specializes in providing discovery services for oncology, for approximately €36million cash (about $38 million), in a deal the buyer said would create a top-tier oncology portfolio for validation of new cancer therapies.